Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 10/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.34 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16159562 | 0.89 | SCN9A (0.38) | SCN9APDK2HDAC4PGRIMPDH2 | |
| SCHEMBL16159806 | 0.85 | SCN9A (0.47) | SCN9AEGFRHDAC4IMPDH2EDNRB | |
| SCHEMBL16159776 | 0.83 | SCN9A (0.56) | SCN9APDK2 | |
| SCHEMBL16159805 | 0.82 | SCN9A (0.51) | SCN9AEGFRPDK2HDAC4CDK4 | |
| SCHEMBL16159336 | 0.78 | SCN9A (0.55) | SCN9AEGFRHDAC4CDK4CDK2 | |
| SCHEMBL14564377 | 0.77 | SCN9A (0.62) | SCN9AEGFRHDAC4CDK4CDK2 | |
| SCHEMBL16159581 | 0.77 | SCN9A (0.36) | SCN9AHDAC4IMPDH2EDNRBEDNRA | |
| SCHEMBL16159343 | 0.76 | SCN9A (0.66) | SCN9AEGFRHDAC4CDK4CDK2 | |
| SCHEMBL14508169 | 0.76 | PDK2 (0.52) | PDK2 | |
| SCHEMBL16159404 | 0.75 | SCN9A (0.64) | SCN9AEGFRHDAC4CDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| WO-2014163173-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC株式会社 (JP) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | HVCN1, VDAC1, SLC26A3 | SCN9A 1007/4885EGFR 1839/4885PDK2 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.